| Aug 13 |
Avidity Biosciences proposes public offering of common stock
|
| Aug 13 |
Avidity Biosciences Announces Proposed Public Offering of Common Stock
|
| Aug 13 |
Company News for Aug 13, 2024
|
| Aug 9 |
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 9 |
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
|
| Aug 9 |
Avidity Biosciences GAAP EPS of -$0.65 beats by $0.14, revenue of $2.05M misses by $0.96M
|
| Aug 9 |
Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
|
| Aug 9 |
Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping...
|
| Aug 5 |
Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
|
| Jul 24 |
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)
|
